Ideas

November 14, 2017

Published by admin_auro at November 14, 2017

Categories

Molecular therapy for middle aged TIIDM patients: Fidarestat,an alodose reductase inhibitor used to control diabetic complications, decreases DNA-PPK expression, suppresses phosphorylation of HSP90a, increases AMPK activity, augments mitochondrial biogenesis and energy metabolism, promotes weight loss and exercise endurance and alleviates TIIDM via down regulation of its target gene, 15/November/2017, 5.26 am

Introduction: What they say A study from the Laboratory of Obesity and Aging Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD […]

November 14, 2017

Published by admin_auro at November 14, 2017

Categories

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Victoza/Saxenda, a drug used in the treatment of TIIDM and Obesity, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 15/September/2017, 5.14 am

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that […]

November 14, 2017

Published by admin_auro at November 14, 2017

Categories

Molecular therapy for Deafness: A therapeutic mix encompassing 1,4-Naphthoquinone/Para-Naphthoquinone, Cholecalciferol, Ajoene and DIM (1,4 PNCAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration, and improves hearing loss via up regulation of its target gene, 15/November/2017, 5.43 am

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Deafness: A therapeutic mix encompassing 1,4-Naphthoquinone/Para-Naphthoquinone, Cholecalciferol, Ajoene and DIM (1,4 PNCAD) increases […]

November 14, 2017

Published by admin_auro at November 14, 2017

Categories

Molecular therapy for body weight control, energy homeostasis and TIIDM: Atorvastatin, a lipid-lowering agent, decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 14/November/2017, 6.41 am

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by […]